| scholarly article | Q13442814 |
| P50 | author | Leanne de Koning | Q92027149 |
| P2093 | author name string | Wolfgang Sommergruber | |
| Cordula Tschuch | |||
| Anne-Lise Peille | |||
| Julia Schueler | |||
| Kerstin Klingner | |||
| Eva Oswald | |||
| Daniel Bug | |||
| Hagen Klett | |||
| P2860 | cites work | HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors | Q24297102 |
| AXL mediates resistance to PI3Kα inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomas | Q24336818 | ||
| Nicalin and its binding partner Nomo are novel Nodal signaling antagonists | Q24563200 | ||
| Patient-derived tumour xenografts as models for oncology drug development | Q24604068 | ||
| dbSNP: the NCBI database of genetic variation | Q24608672 | ||
| ERK2-binding domain is required for phosphorylation of EBITEIN1, a potential downstream interactor of ERK2. | Q51951061 | ||
| Proline-Rich Protein Tyrosine Kinase 2 in Inflammation and Cancer. | Q54111596 | ||
| KRAS mutation as the biomarker of response to chemotherapy and EGFR-TKIs in patients with advanced non-small cell lung cancer: clues for its potential use in second-line therapy decision making. | Q54440829 | ||
| Young male with fanconi anemia and EGFR-mutant non-small-cell lung cancer. | Q55069907 | ||
| SNPnexus: assessing the functional relevance of genetic variation to facilitate the promise of precision medicine. | Q55518761 | ||
| STAT1‑HDAC4 signaling induces epithelial‑mesenchymal transition and sphere formation of cancer cells overexpressing the oncogene, CUG2 | Q58746026 | ||
| STRING v11: protein–protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets | Q60469724 | ||
| First- and Second-Generation EGFR-TKIs Are All Replaced to Osimertinib in Chemo-Naive Mutation-Positive Non-Small Cell Lung Cancer? | Q60921601 | ||
| Whole transcriptome targeted gene quantification provides new insights on pulmonary sarcomatoid carcinomas | Q64065228 | ||
| Epidermal growth factor induces STAT1 expression to exacerbate the IFNr-mediated PD-L1 axis in epidermal growth factor receptor-positive cancers | Q90408760 | ||
| Epithelial-to-mesenchymal transition: lessons from development, insights into cancer and the potential of EMT-subtype based therapeutic intervention | Q92791289 | ||
| EMT: A mechanism for escape from EGFR-targeted therapy in lung cancer | Q93007764 | ||
| Dock-family exchange factors in cell migration and disease | Q38229273 | ||
| Anexelekto (AXL) Increases Resistance to EGFR-TKI and Activation of AKT and ERK1/2 in Non-Small Cell Lung Cancer Cells | Q38742188 | ||
| Regulation of the MET oncogene: molecular mechanisms | Q38746401 | ||
| Elevated RET expression enhances EGFR activation and mediates EGFR inhibitor resistance in head and neck squamous cell carcinoma | Q38777317 | ||
| The Roles of Histone Demethylase UTX and JMJD3 (KDM6B) in Cancers: Current Progress and Future Perspectives | Q38837856 | ||
| A 15-gene signature for prediction of colon cancer recurrence and prognosis based on SVM. | Q39081165 | ||
| Regulation of EMT by STAT3 in gastrointestinal cancer (Review). | Q39093583 | ||
| EGFR-activating mutations correlate with a Fanconi anemia-like cellular phenotype that includes PARP inhibitor sensitivity | Q39106976 | ||
| Nodal Signaling as a Developmental Therapeutics Target in Oncology | Q39281368 | ||
| EGFR expression is linked to osteopontin and Nf-κB signaling in clear cell renal cell carcinoma | Q39303908 | ||
| NCOA2 is a candidate target gene of 8q gain associated with clinically aggressive prostate cancer. | Q40073572 | ||
| Resistance to EGFR-targeted therapy by Ets-1 inactivation | Q42910481 | ||
| YAP-Dependent AXL Overexpression Mediates Resistance to EGFR Inhibitors in NSCLC. | Q43632068 | ||
| Co-expression of Rho guanine nucleotide exchange factor 5 and Src associates with poor prognosis of patients with resected non-small cell lung cancer | Q43934553 | ||
| A TNF-JNK-Axl-ERK signaling axis mediates primary resistance to EGFR inhibition in glioblastoma. | Q46093038 | ||
| Acquisition of EGFR TKI resistance and EMT phenotype is linked with activation of IGF1R/NF-κB pathway in EGFR-mutant NSCLC. | Q47119773 | ||
| Mechanisms of resistance to irreversible epidermal growth factor receptor tyrosine kinase inhibitors and therapeutic strategies in non-small cell lung cancer | Q47146662 | ||
| Next-generation sequencing reveals novel resistance mechanisms and molecular heterogeneity in EGFR-mutant non-small cell lung cancer with acquired resistance to EGFR-TKIs | Q47374429 | ||
| ErbB Receptors and Cancer | Q47974787 | ||
| Post-Translational Modifications of RelB NF-κB Subunit and Associated Functions | Q26751459 | ||
| Ligand-Independent EGFR Signaling | Q26797495 | ||
| EGFR mutation and resistance of non-small-cell lung cancer to gefitinib | Q27824829 | ||
| Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors | Q27851633 | ||
| Mechanisms of resistance to EGFR-targeted drugs: lung cancer | Q28077415 | ||
| Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway | Q28203777 | ||
| A family of IFN-γ-inducible 65-kD GTPases protects against bacterial infection | Q28593668 | ||
| limma powers differential expression analyses for RNA-sequencing and microarray studies | Q29617988 | ||
| Antitumor activity of selective MEK1/2 inhibitor AZD6244 in combination with PI3K/mTOR inhibitor BEZ235 in gefitinib-resistant NSCLC xenograft models | Q33820374 | ||
| Loss of EGFR signaling regulated miR-203 promotes prostate cancer bone metastasis and tyrosine kinase inhibitors resistance | Q33977056 | ||
| Combining docking site and phosphosite predictions to find new substrates: identification of smoothelin-like-2 (SMTNL2) as a c-Jun N-terminal kinase (JNK) substrate | Q34044220 | ||
| Patient-derived xenograft models: an emerging platform for translational cancer research | Q34205518 | ||
| NormaCurve: a SuperCurve-based method that simultaneously quantifies and normalizes reverse phase protein array data | Q34325755 | ||
| EGFR inhibition evokes innate drug resistance in lung cancer cells by preventing Akt activity and thus inactivating Ets-1 function | Q35895556 | ||
| Xenome--a tool for classifying reads from xenograft samples. | Q36022173 | ||
| STAT1 Activation Is Enhanced by Cisplatin and Variably Affected by EGFR Inhibition in HNSCC Cells | Q36030906 | ||
| Ranking novel cancer driving synthetic lethal gene pairs using TCGA data | Q36082825 | ||
| STAT1 gene expression is enhanced by nuclear EGFR and HER2 via cooperation with STAT3 | Q36351195 | ||
| An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance | Q36597042 | ||
| Tumor models for efficacy determination | Q36623519 | ||
| Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease | Q36660669 | ||
| Radiotherapy diagnostic biomarkers in radioresistant human H460 lung cancer stem-like cells | Q36844321 | ||
| The Ensembl Variant Effect Predictor | Q36970975 | ||
| New cast for a new era: preclinical cancer drug development revisited. | Q37123902 | ||
| Prognostic value of a newly identified MALAT1 alternatively spliced transcript in breast cancer | Q37174025 | ||
| The Rho guanine nucleotide exchange factor ARHGEF5 promotes tumor malignancy via epithelial-mesenchymal transition | Q37306549 | ||
| Requirement for NF-kappaB signalling in a mouse model of lung adenocarcinoma | Q37428076 | ||
| IL-27 inhibits epithelial-mesenchymal transition and angiogenic factor production in a STAT1-dominant pathway in human non-small cell lung cancer | Q37532498 | ||
| ERK1/2 blockade prevents epithelial-mesenchymal transition in lung cancer cells and promotes their sensitivity to EGFR inhibition | Q37661108 | ||
| Next-generation sequencing of non-small cell lung cancer using a customized, targeted sequencing panel: Emphasis on small biopsy and cytology | Q37736978 | ||
| The tumor stroma as mediator of drug resistance--a potential target to improve cancer therapy? | Q37878534 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 7 | |
| P921 | main subject | non-small-cell lung carcinoma | Q3658562 |
| P577 | publication date | 2019-07-18 | |
| P1433 | published in | Cells | Q27724621 |
| P1476 | title | Induction of Acquired Resistance towards EGFR Inhibitor Gefitinib in a Patient-Derived Xenograft Model of Non-Small Cell Lung Cancer and Subsequent Molecular Characterization | |
| P478 | volume | 8 |
| Q98188949 | Genipin suppression of growth and metastasis in hepatocellular carcinoma through blocking activation of STAT-3 |
| Q92678621 | Sodium cantharidate targets STAT3 and abrogates EGFR inhibitor resistance in osteosarcoma |
| Q93173743 | Triptolide inhibits epithelial‑mesenchymal transition and induces apoptosis in gefitinib‑resistant lung cancer cells |
Search more.